A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment-Reference-Cited by-同舟云学术

A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment

Published:2015-06-22 Issue:2 Volume:57 Page:370-375
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Faber Edgar,Divoká Martina,Skoumalová Ivana,Novák Martin,Marešová Ivana,Mičová Kateřina,Friedecký David,Adam Tomáš,Jarošová Marie,Indrák Karel

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2015.1056184

Reference16 articles.

1. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

2. Interferon-alpha in chronic myeloid leukemia revisited: A long-term retrospective study in Central and Northern Moravia

3. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

4. Safety and efficacy of imatinib cessation for CML patients with stable undetectable minimal residual disease: results from the TWISTER study

Cited by 22 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment with low-dose tyrosine kinase inhibitors due to significant haematologic toxicity in patients with CML with prolonged treatment failure prevents haematologic progression;Hematology, Transfusion and Cell Therapy;2024-07

2. Challenges in management of older patients with chronic myeloid leukemia;Leukemia & Lymphoma;2024-04-23

3. Chronic Myeloid Leukemia, Version 2.2024, NCCN Clinical Practice Guidelines in Oncology;Journal of the National Comprehensive Cancer Network;2024-02

4. Imatinib-induced severe hematological toxicity: Prolonged myelosuppression resulting from extraordinary sensitivity in an old age;European Journal of Inflammation;2023-02-15

5. Russian Prospective Non-Randomized Clinical Study on Dose Reduction of Tyrosine Kinase Inhibitors with Subsequent Complete Therapy Discontinuation in Chronic Myeloid Leukemia Patients with Stable Deep Molecular Response (READIT-2020): Background, Aim, Main Objectives, Design, and Expected Results;Clinical oncohematology;2022